Single agent nanoparticle for radiotherapy and radio-photothermal therapy in anaplastic thyroid cancer

Biomaterials

Volumn 57, Issue , 2015, Pages 41-49

  Zhou, Min ^a   Chen, Yunyun ^a   Adachi, Makoto ^a   Wen, Xiaoxia ^a   Erwin, Bill ^a   Mawlawi, Osama ^a   Lai, Stephen Y ^a   Li, Chun ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Anaplastic thyroid cancer; Copper 64; Dosimetry; Photothermal ablation therapy; Positron emission tomography; Radiotherapy

Indexed keywords

CHEMOTHERAPY; COPPER; DISEASES; DOSIMETRY; INFRARED DEVICES; INFRARED LASERS; MAMMALS; NANOPARTICLES; RADIOTHERAPY; TUMORS;

ACUTE TOXIC EFFECTS; INTRATUMORAL INJECTION; NEAR-INFRARED LASERS; PHOTOTHERMAL ABLATION THERAPY; PHOTOTHERMAL THERAPY; PLASMONIC PROPERTIES; THERAPEUTIC EFFICACY; THYROID CANCERS;

POSITRON EMISSION TOMOGRAPHY;

COPPER 64; COPPER NANOPARTICLE; COPPER SULFIDE NANOPARTICLE; MACROGOL; NANOPARTICLE; UNCLASSIFIED DRUG; COPPER; CUPROUS SULFIDE; MACROGOL DERIVATIVE; SULFIDE;

ANAPLASTIC THYROID CANCER; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER RADIOTHERAPY; COMPUTER ASSISTED EMISSION TOMOGRAPHY; CONTROLLED STUDY; DOSIMETRY; DRUG COATING; DRUG DISTRIBUTION; HUMAN; HUMAN CELL; LOW LEVEL LASER THERAPY; MALE; MICRO-COMPUTED TOMOGRAPHY; MOUSE; NONHUMAN; PHOTOTHERAPY; PHOTOTHERMAL THERAPY; PRIORITY JOURNAL; SURVIVAL RATE; TUMOR GROWTH; TUMOR VOLUME; TUMOR XENOGRAFT; ANIMAL; CHEMISTRY; MULTIMODALITY CANCER THERAPY; NUDE MOUSE; PATHOLOGY; POSITRON EMISSION TOMOGRAPHY; PROCEDURES; RADIATION RESPONSE; THYROID CARCINOMA, ANAPLASTIC; THYROID GLAND; THYROID NEOPLASMS; TUMOR CELL LINE; ULTRASTRUCTURE;

ANIMALIA; MURINAE; MUS;

ANIMALS; CELL LINE, TUMOR; COMBINED MODALITY THERAPY; COPPER; COPPER RADIOISOTOPES; HUMANS; LASER THERAPY; MALE; MICE; MICE, NUDE; NANOPARTICLES; PHOTOTHERAPY; POLYETHYLENE GLYCOLS; POSITRON-EMISSION TOMOGRAPHY; SULFIDES; THYROID CARCINOMA, ANAPLASTIC; THYROID GLAND; THYROID NEOPLASMS;

EID: 84928939824     PISSN: 01429612     EISSN: 18785905     Source Type: Journal    
DOI: 10.1016/j.biomaterials.2015.04.013     Document Type: Article

References (41)

1. Siegel R., Naishadham D., Jemal A. Cancer statistics, 2013. CA Cancer J Clin 2013, 63:11-30.
2. Chen A.Y., Jemal A., Ward E.M. Increasing incidence of differentiated thyroid cancer in the united states, 1988-2005. Cancer 2009, 115:3801-3807.
3. Society AC Cancer facts & figures 2010 2010, American Cancer Society, Atlanta, GA.
4. Smallridge R.C., Copland J.A. Anaplastic thyroid carcinoma: pathogenesis and emerging therapies. Clin Oncol R Coll Radiol 2010, 22:486-497.
5. McIver B., Hay I.D., Giuffrida D.F., Dvorak C.E., Grant C.S., Thompson G.B., et al. Anaplastic thyroid carcinoma: a 50-year experience at a single institution. Surgery 2001, 130:1028-1034.
6. Bhatia A., Rao A., Ang K.K., Garden A.S., Morrison W.H., Rosenthal D.I., et al. Anaplastic thyroid cancer: clinical outcomes with conformal radiotherapy. Head Neck 2010, 32:829-836.
7. Sherman E.J., Lim S.H., Ho A.L., Ghossein R.A., Fury M.G., Shaha A.R., et al. Concurrent doxorubicin and radiotherapy for anaplastic thyroid cancer: a critical re-evaluation including uniform pathologic review. Radiother Oncol 2011, 101:425-430.
8. Gule M.K., Chen Y.Y., Sano D., Frederick M.J., Zhou G., Zhao M., et al. Targeted therapy of VEGFR2 and EGFR significantly inhibits growth of anaplastic thyroid cancer in an orthotopic murine model. Clin Cancer Res 2011, 17:2281-2291.
9. Isham C.R., Bossou A.R., Negron V., Fisher K.E., Kumar R., Marlow L., et al. Pazopanib enhances paclitaxel-induced mitotic catastrophe in anaplastic thyroid cancer. Sci Transl Med 2013, 5:166ra3.
10. Melancon M.P., Zhou M., Li C. Cancer theranostics with near-infrared light-activatable multimodal nanoparticles. Acc Chem Res 2011, 44:947-956.
11. Lu W., Xiong C., Zhang G., Huang Q., Zhang R., Zhang J.Z., et al. Targeted photothermal ablation of murine melanomas with melanocyte-stimulating hormone analog-conjugated hollow gold nanospheres. Clin Cancer Res 2009, 15:876-886.
12. Melancon M.P., Lu W., Yang Z., Zhang R., Cheng Z., Elliot A.M., et al. Invitro and invivo targeting of hollow gold nanoshells directed at epidermal growth factor receptor for photothermal ablation therapy. Mol Cancer Ther 2008, 7:1730-1739.
13. Melancon M.P., Elliott A., Ji X., Shetty A., Yang Z., Tian M., et al. Theranostics with multifunctional magnetic gold nanoshells: photothermal therapy and T2* magnetic resonance imaging. Invest Radiol 2011, 46:132-140.
14. 64Cu]CuS nanoparticle platform for simultaneous micro-PET/CT imaging and photothermal ablation therapy. JAm Chem Soc 2010, 132:15351-15358.
15. Song S.L., Xiong C.Y., Zhou M., Lu W., Huang Q., Ku G., et al. Small-animal PET of tumor damage induced by photothermal ablation with (64)Cu-bis-dota-hypericin. JNucl Med 2011, 52:792-799.
16. Ku G., Zhou M., Song S.L., Huang Q., Hazle J., Li C. Copper sulfide nanoparticles as a new class of photoacoustic contrast agent for deep tissue imaging at 1064 nm. Acs Nano 2012, 6:7489-7496.
17. Chang C.H., Stabin M.G., Chang Y.J., Chen L.C., Chen M.H., Chang T.J., et al. Comparative dosimetric evaluation of nanotargeted (188)Re-(DXR)-liposome for internal radiotherapy. Cancer Biother Radiopharm 2008, 23:749-758.
18. Chanda N., Kan P., Watkinson L.D., Shukla R., Zambre A., Carmack T.L., et al. Radioactive gold nanoparticles in cancer therapy: therapeutic efficacy studies of GA-198AuNP nanoconstruct in prostate tumor-bearing mice. Nanomedicine 2010, 6:201-209.
19. Hong H., Zhang Y., Sun J., Cai W. Molecular imaging and therapy of cancer with radiolabeled nanoparticles. Nano Today 2009, 4:399-413.
20. Anderson C.J., Ferdani R. Copper-64 radiopharmaceuticals for PET imaging of cancer: advances in preclinical and clinical research. Cancer Biother Radiopharm 2009, 24:379-393.
21. Bryan J.N., Jia F., Mohsin H., Sivaguru G., Anderson C.J., Miller W.H., et al. Monoclonal antibodies for copper-64 PET dosimetry and radioimmunotherapy. Cancer Biol Ther 2011, 11:1001-1007.
22. Lewis J.S., Laforest R., Buettner T.L., Song S.K., Fujibayashi Y., Connett J.M., et al. Copper-64-diacetyl-bis(N-4-methylthiosemicarbazone): an agent for radiotherapy. Proc Nat Acad Sci U. S. A 2001, 98:1206-1211.
23. Shokeen M., Anderson C.J. Molecular imaging of cancer with copper-64 radiopharmaceuticals and positron emission tomography (PET). Acc Chem Res 2009, 42:832-841.
24. Laforest R., Dehdashti F., Lewis J.S., Schwarz S.W. Dosimetry of 60/61/62/64Cu-ATSM: a hypoxia imaging agent for PET. Eur J Nucl Med Mol Imaging 2005, 32:764-770.
25. 64Cu-labeled folate-conjugated shell cross-linked nanoparticles for tumor imaging and radiotherapy: synthesis, radiolabeling, and biologic evaluation. JNucl Med 2005, 46:1210-1218.
26. Zhao M., Sano D., Pickering C.R., Jasser S.A., Henderson Y.C., Clayman G.L., et al. Assembly and initial characterization of a panel of 85 genomically validated cell lines from diverse head and neck tumor sites. Clin Cancer Res 2011, 17:7248-7264.
27. Stabin M.G., Sparks R.B., Crowe E. Olinda/exm: the second-generation personal computer software for internal dose assessment in nuclear medicine. JNuc Med 2005, 46:1023-1027.
28. Adachi M., Cui C., Dodge C.T., Bhayani M.K., Lai S.Y. Targeting Stat3 inhibits growth and enhances radiosensitivity in head and neck squamous cell carcinoma. Oral Oncol 2012, 48:1220-1226.
29. Obata A., Kasamatsu S., Lewis J.S., Furukawa T., Takamatsu S., Toyohara J., et al. Basic characterization of Cu-64-ATSM as a radiotherapy agent. Nucl Med Biol 2005, 32:21-28.
30. ODonoghue J.A., Wheldon T.E. Targeted radiotherapy using auger electron emitters. Phys Med Biol 1996, 41:1973-1992.
31. Blower P.J., Lewis J.S., Zweit J. Copper radionuclides and radiopharmaceuticals in nuclear medicine. Nucl Med Biol 1996, 23:957-980.
32. You J., Zhang R., Xiong C., Zhong M., Melancon M., Gupta S., et al. Effective photothermal chemotherapy using doxorubicin-loaded gold nanospheres that target EphB4 receptors in tumors. Cancer Res 2012, 72:4777-4786.
33. Liu Z., Cai W.B., He L.N., Nakayama N., Chen K., Sun X.M., et al. Invivo biodistribution and highly efficient tumour targeting of carbon nanotubes in mice. Nat Nanotechnol 2007, 2:47-52.
34. Pressly E.D., Rossin R., Hagooly A., Fukukawa K.I., Messmore B.W., Welch M.J., et al. Structural effects on the biodistribution and positron emission tomography (PET) imaging of well-defined Cu-64-labeled nanoparticles comprised of amphiphilic block graft copolymers. Biomacromolecules 2007, 8:3126-3134.
35. Schipper M.L., Cheng Z., Lee S.W., Bentolila L.A., Iyer G., Rao J.H., et al. MicroPET -based biodistribution of quantum dots in living mice. JNucl Med 2007, 48:1511-1518.
36. Schipper M.L., Iyer G., Koh A.L., Cheng Z., Ebenstein Y., Aharoni A., et al. Particle size, surface coating, and pegylation influence the biodistribution of quantum dots in living mice. Small 2009, 5:126-134.
37. Schluep T., Hwang J., Hildebrandt I.J., Czernin J., Choi C.H.J., Alabi C.A., et al. Pharmacokinetics and tumor dynamics of the nanoparticle IT-101 from PET imaging and tumor histological measurements. Proc Natl Acad Sci U. S. A 2009, 106:11394-11399.
38. van der Zee J., Gonzalez D.G., van Rhoon G.C., van Dijk J.D.P., van Putten W.L.J., Hart A.A.M., et al. Comparison of radiotherapy alone with radiotherapy plus hyperthermia in locally advanced pelvic tumours: a prospective, randomised, multicentre trial. Lancet 2000, 355:1119-1125.
39. Horsman M.R., Overgaard J. Hyperthermia: a potent enhancer of radiotherapy. Clin Oncol R Coll Radiol 2007, 19:418-426.
40. Sun X.R., Xing L.G., Ling C.C., Li G.C. The effect of mild temperature hyperthermia on tumour hypoxia and blood perfusion: relevance for radiotherapy, vascular targeting and imaging. Int J Hyperther 2010, 26:224-231.
41. Tecchio C., Colato C., Bonifacio M., Krampera M., Maluta S., Pizzolo G., et al. Plasmacytoid dendritic cell leukemia: a rapidly evolving disease presenting with skin lesions sensitive to radiotherapy plus hyperthermia. Oncologist 2009, 14:1205-1208.